RCT | Cisplatin–gemcitabine improves 3-year progression-free survival in N2–3 nasopharyngeal carcinoma compared to cisplatin–fluorouracil

Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma – ESMO

Commentary on Twitter

NOW OF: Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialhttps://t.co/n6WalQiRfo pic.twitter.com/vE4VASUIgM

— The Lancet Oncology (@TheLancetOncol) June 5, 2023